Behavioral intervention versus pharmacotherapy or their combinations in the management of overactive bladder dysfunction
- PMID: 20029638
- PMCID: PMC2796220
- DOI: 10.1155/2009/345324
Behavioral intervention versus pharmacotherapy or their combinations in the management of overactive bladder dysfunction
Abstract
Overactive bladder syndrome (OAB) refers to individuals with the following symptoms: urinary urgency, increased urinary frequency, and urge incontinence. These symptoms are not life threatening but can cause embarrassment and significantly impact quality of life. There are numerous treatment options for OAB, including behavioral therapy, traditional pharmacological therapy or a combination of the two. These options are considered the mainstay of treatment for OAB. We carried out a comprehensive systematic review of the available literature on the effectiveness of behavioral intervention, anticholinergic drugs, and their combination in the management of adults with overactive bladder, with emphasis on results from clinical trials and primary literature. Each treatment intervention is efficacious, and the choice should be based on the patient's severity of symptoms, tolerability, compliance and satisfaction with the treatment. Based on available literature, management of OAB using a combination of behavioral therapy and drug intervention is the most efficacious in terms of patient satisfaction, perceived improvement, and reduction of bladder symptoms. It is also the most practical and cost effective for optimal management of patients with OAB. Pharmacological treatment, in addition to behavioral therapy, remains important in the management of adults with OAB syndrome.
Similar articles
-
Treatments for overactive bladder: focus on pharmacotherapy.J Obstet Gynaecol Can. 2012 Nov;34(11):1092-1101. doi: 10.1016/S1701-2163(16)35440-8. J Obstet Gynaecol Can. 2012. PMID: 23231848
-
Overactive bladder--a practical approach to evaluation and management.J Med Liban. 2004 Oct-Dec;52(4):220-6. J Med Liban. 2004. PMID: 16432986 Review.
-
[The new era in the pharmacological treatment of overactive bladder (OAB): mirabegron--a new selective beta3agonist].Ginekol Pol. 2014 Mar;85(3):214-9. doi: 10.17772/gp/1716. Ginekol Pol. 2014. PMID: 24783434 Review. Polish.
-
Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom Complex.Eur Urol Focus. 2020 May 15;6(3):522-530. doi: 10.1016/j.euf.2019.09.020. Epub 2019 Oct 15. Eur Urol Focus. 2020. PMID: 31623981 Review.
-
Correlation between psychological stress levels and the severity of overactive bladder symptoms.BMC Urol. 2015 Mar 8;15:14. doi: 10.1186/s12894-015-0009-6. BMC Urol. 2015. PMID: 25887525 Free PMC article.
Cited by
-
Manipulating the circadian and sleep cycles to protect against metabolic disease.Front Endocrinol (Lausanne). 2015 Mar 23;6:35. doi: 10.3389/fendo.2015.00035. eCollection 2015. Front Endocrinol (Lausanne). 2015. PMID: 25852644 Free PMC article. Review.
-
Effect of electroacupuncture versus pelvic floor muscle training plus solifenacin for moderate and severe mixed urinary incontinence in women: a study protocol.BMC Complement Altern Med. 2014 Aug 15;14:301. doi: 10.1186/1472-6882-14-301. BMC Complement Altern Med. 2014. PMID: 25128002 Free PMC article. Clinical Trial.
-
The Costs and Healthcare Resource Utilization Associated with Anticholinergic Burden in Long-Stay Nursing Home Residents with Overactive Bladder in the US.Pharmacoecon Open. 2021 Dec;5(4):727-736. doi: 10.1007/s41669-021-00281-8. Epub 2021 Jul 13. Pharmacoecon Open. 2021. PMID: 34255290 Free PMC article.
-
Effects of two nonpharmacological treatments on the sleep quality of women with nocturia: a randomized controlled clinical trial.Int Urogynecol J. 2019 Feb;30(2):279-286. doi: 10.1007/s00192-018-3584-8. Epub 2018 Mar 6. Int Urogynecol J. 2019. PMID: 29508046 Clinical Trial.
-
Drugs for the overactive bladder: are there differences in persistence and compliance?Transl Androl Urol. 2017 Jun;6(3):597-601. doi: 10.21037/tau.2017.03.90. Transl Androl Urol. 2017. PMID: 28725606 Free PMC article. No abstract available.
References
-
- Hellstrom L, Ekelund P, Milsom I, Mellstrom D. The prevalenc of urinary incontinence and use of incontinence aids in 85-year-old men and women. Age and Ageing. 1990;19(6):383–389. - PubMed
-
- Brown JS, Seeley DG, Fong J, Black DM, Ensrud KE, Grady D. Urinary incontinence in older women: who is at risk? Obstetrics and Gynecology. 1996;87(5, part 1):715–721. - PubMed
-
- Lagace EA, Hansen W, Hickner JM. Prevalence and severity of urinary incontinence in ambulatory adults: an UPRNet study. Journal of Family Practice. 1993;36(6):610–614. - PubMed
-
- Ouslander JG, Kane RL, Abrass IB. Urinary incontinence in elderly nursing home patients. Journal of the American Medical Association. 1982;248(10):1194–1198. - PubMed
-
- Wilson L, Brown JS, Shin GP, Luc KO, Subak LL. Annual direct cost of urinary incontinence. Obstetrics and Gynecology. 2001;98(3):398–406. - PubMed
LinkOut - more resources
Full Text Sources